lurbinectedin (PM01183)

DRUG9 trials

Sponsors

PharmaMar

Conditions

Advanced Solid TumorsEndometrial AdenocarcinomasMetastatic Breast CancerMetastatic Colorectal CancerNeuroendocrine TumorsNon-Small Cell Lung Cancer (NSCLC)Ovarian CancerPancreatic Cancer

Phase 1

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

CompletedNCT01970540

PharmaMarEndometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy

Start: 2011-05-25End: 2017-08-09Updated: 2020-03-09

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

CompletedNCT01970553

PharmaMarSpecific Advanced Solid Tumors

Start: 2011-05-31End: 2013-10-31Updated: 2015-04-01

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

CompletedNCT01980667

PharmaMarAdvanced Solid Tumors

Start: 2014-07-30End: 2017-01-05Updated: 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

CompletedNCT02210364

PharmaMarMetastatic Breast Cancer, Metastatic Colorectal Cancer, Pancreatic Cancer

Start: 2013-04-30End: 2016-10-31Updated: 2016-12-14

Phase 2

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

CompletedNCT01951157

PharmaMarNon-Small Cell Lung Cancer (NSCLC)

Start: 2013-09-11End: 2016-11-30Updated: 2019-09-24

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

CompletedNCT02451007

PharmaMarSolid Tumors

Start: 2015-08-12End: 2016-08-19Updated: 2019-11-19

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

CompletedNCT02454972

PharmaMarAdvanced Solid Tumors

Start: 2015-08-25End: 2020-09-18Updated: 2023-03-02

Phase 3

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

CompletedNCT02421588

PharmaMarOvarian Cancer

Start: 2015-05-31End: 2018-10-12Updated: 2020-04-03

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

CompletedNCT02566993

PharmaMarSmall-cell Lung Cancer

Start: 2016-08-30End: 2020-02-24Updated: 2021-10-28

Related Papers

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.

2024-02-134 citations

Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.

2023-09-014 citations

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

2023-08-096 citations

A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).

Journal of Clinical Oncology2023-06-0121 citations

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.

Journal of Clinical Oncology2023-06-011 citations

Safety analysis of lurbinectedin versus topotecan in elderly patients.

Journal of Clinical Oncology2023-06-01

Abstract 6247: Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response

Cancer Research2023-04-043 citations

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

2022-10-1477 citations

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.

2022-08-289 citations

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

European Journal of Cancer2022-07-1019 citations

Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.

Journal of Clinical Oncology2022-06-016 citations

Efficacy of lurbinectedin in a clinical trial versus other standard of care in a real-world comparator arm in relapsed/refractory small cell lung cancer patients.

Journal of Clinical Oncology2022-06-011 citations

Lurbinectedin in patients with pretreated<i> BRCA</i>1/2-associated metastatic breast cancer: Results from a phase II basket study.

Journal of Clinical Oncology2022-06-01

Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.

2021-11-059 citations

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).

2021-09-1151 citations

A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.

2021-08-285 citations

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

Investigational New Drugs2021-03-1119 citations

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical Cancer Research2020-12-0788 citations

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m<sup>2</sup> versus 40 mg/m<sup>2</sup> in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

Journal of Gynecologic Oncology2020-11-127 citations

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

2020-10-1029 citations

14 more papers not shown